Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease schizophrenia
Symptom C0085631|agitation
Sentences 29
PubMedID- 22226343 Objective: to describe the efficacy of inhaled loxapine for the treatment of agitation associated with schizophrenia or bipolar disorder using different examples of effect size (es).
PubMedID- 23723707 Administered via a single-use device, inhaled loxapine was tested in randomized controlled trials in agitation associated with schizophrenia or bipolar mania; doses of 5 mg and 10 mg were found to be efficacious, with an apparent dose response.
PubMedID- 25859275 Recently, inhaled loxapine (adasuve) has been approved by the food and drug administration and european medical agency for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults.
PubMedID- 21199198 This effect size is in the range observed for intramuscular administration of other antipsychotics for agitation associated with schizophrenia or bipolar disorder.
PubMedID- 26517202 Treatment with aripiprazole lauroxil resulted in decreases in agitation and hostility in patients with schizophrenia and this antihostility effect appears to be independent of a general antipsychotic effect.
PubMedID- 22229963 Acute agitation in patients with schizophrenia or bipolar disorder is an important clinical management problem.
PubMedID- 24600225 For example, in a pilot study of eleven patients, where the first measured time points were 15 seconds for initial disintegration and 60 seconds for complete disintegration, chue et al found that the mean time to initial disintegration was 15.78 seconds and mean time to complete disintegration was 0.97 minutes.7 it has been suggested that odo may have a faster onset of action and be more appropriate for the treatment of acute agitation in patients with schizophrenia or bipolar disorder.
PubMedID- 24745666 Background: loxapine, a first-generation antipsychotic, delivered with a novel inhalation delivery device developed for the acute treatment of agitation in patients with schizophrenia or bipolar disorder was evaluated in subjects with asthma or chronic obstructive pulmonary disease (copd).
PubMedID- 24765654 Olanzapine is an atypical antipsychotic agent used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia.9 according to biopharmaceutical classification system (bcs), olz is classified as a class ii drug (low solubility, high permeability) with water solubility around 43 mg/l.10 olz has been suggested to crystallize in more than 50 different crystalline forms, including anhydrates, hydrates, and solvates.11,12 in this study, anhydrous olz form i, the most stable form and currently used in pharmaceutical formulations, was selected for study.
PubMedID- 24063534 We propose that hypocalcemia and agitation in patients with schizophrenia may derive from the 22q11.2 deletion, particularly when these phenotypes are coupled with schizophrenia-like symptoms.
PubMedID- 23538290 agitation is common in patients with acute schizophrenia and bipolar disorder, and rapid and effective treatment of acute agitation is an important clinical goal.
PubMedID- 26090227 In adults, olanzapine im has been shown to be efficacious in the management of agitation associated with schizophrenia, borderline personality disorder, bipolar disorder, and drug- and alcohol-using patients .
PubMedID- 22233697 This randomized, parallel-group, open study investigated the efficacy and safety of risperidone oral solution (ris-os) in combination with clonazepam and intramuscular haloperidol for the treatment of acute agitation in patients with schizophrenia, and the study explored the possibility of decreasing the efficacy of an acute 6-week treatment by switching intramuscular haloperidol injection to ris-os.
PubMedID- 23311957 Olanzapine rapid im injection preparation demonstrated efficacy and safety in patients who had exacerbation of schizophrenia with acute psychotic agitation, and it could be a new option for treatment of schizophrenia with severe agitation, which cannot be treated with oral medication, in japan.
PubMedID- 22346347 It has been suggested that odo may have a faster onset of action and be more appropriate for the treatment of acute agitation in schizophrenia or bipolar disorder.23 however, odo was found to be bioequivalent to the same dosage of sot with the maximum observed concentration and time taken to reach maximum observed concentration being almost indistinguishable between the two formulations.23–25 for example, although bergstrom et al found more rapid initial absorption into the blood of olanzapine from odo, the difference in means between odo and sot for maximum plasma concentration and area under the curve of plasma concentration over time were all <10% and the 90% confidence intervals for the ratio of mean values were within the standard bioequivalence limits of 0.80–1.25.
PubMedID- 20156413 Safety data from the first 21 months of olanzapine im, approved in the united states for the treatment of agitation associated with schizophrenia and bipolar disorder, are presented.
PubMedID- 25311499 Aripiprazole for acutetreatment of agitation with schizophrenia or bipolar i disorder), setting a precedent forviewing agitation as a distinct syndrome.
PubMedID- 22558126 This model has been classically linked to motor agitation and one of the schizophrenia positive symptoms .
PubMedID- 25219417 Vaginal application of orodispersible drugs for schizophrenia presenting with agitation and aggression.
PubMedID- 24445245 Three studies assessed the efficacy of aripiprazole on agitation symptoms in patients with schizophrenia and for which a dose of aripiprazole between 1 and 15mg showed significant efficacy compared to placebo.
PubMedID- 22815915 Olanzapine (db00334) approved in 1996, is an atypical antipsychotic agent, which is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia , .
PubMedID- 24600269 However, population-based studies of adults have failed to demonstrate significant pharmacokinetic differences between smokers and nonsmokers,9 while stimmel found that the pharmacokinetics of ziprasidone show no differences with regard to gender or age.17 ziprasidone is also available in an injectable formulation for intramuscular use, which is approved for the acute treatment of agitation associated with schizophrenia in adults.
PubMedID- 23675355 The overall prevalence of agitation in patients with schizophrenia or mood disorder is about 11–13%, with even higher rates among individuals with alcoholism (25%) or substance misuse (35%) (swanson et al., 1990), dementia (24–45%), anxiety disorders (20–30%).
PubMedID- 26501204 A new formulation of loxapine (inhaled loxapine aerosol for deep lung absorption) has been approved in the united states (usa) and european union (eu) for the rapid treatment of agitation in adults with schizophrenia and bipolar disorder.
PubMedID- 24571828 In contrast to agitation associated with schizophrenia or bipolar mania, no agents have yet been approved by regulatory agencies for the treatment of persistent aggressive behavior.
PubMedID- 21764872 Inhaled loxapine reduces acute agitation in people with schizophrenia compared with placebo.
PubMedID- 23922840 Psychotomimetic drugs, such as non-competitive nmdar antagonists mk801 and pcp can exacerbate the psychomotor agitation in schizophrenia , , such as their effects in gat1 ko mice.
PubMedID- 20856920 A rapid-acting, nondepot intramuscular preparation of olanzapine is also available and approved for the treatment of agitation associated with schizophrenia and bipolar mania.
PubMedID- 26587235 However, adding or switching to aripiprazole may cause worsening of psychotic symptoms, agitation or activation in patients with established schizophrenia or schizoaffective disorder.

Page: 1